Turkey Company Roundup: Novartis Malaria Plans, MSD R&D Boost
This article was originally published in PharmAsia News
Novartis aims to double its exports from Turkey in five years by locally producing a malaria drug, while MSD plans to channel more R&D investments to the country. Meanwhile, the CEO of a Turkish pharmaceutical company gets 30 months’ imprisonment from a U.S. federal court, Bayer faces a lawsuit in Turkey and Alvimedica gets U.S. FDA approval for two catheter products.
You may also be interested in...
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.
The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.
Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.